SCHEMBL3151982

SCHEMBL3151982

O=C(O)Oc1cnc2ccccc2n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.65
KMT2A Q03164 4/20 0.65
HTT P42858 10/20 0.58
ALDH1A1 P00352 6/20 0.58
HPGD P15428 2/20 0.55
ALOX15 P16050 1/20 0.55
HSD17B10 Q99714 1/20 0.55
SMN1; SMN2 Q16637 3/20 0.53
KDM4E B2RXH2 3/20 0.53
RHOA P61586 1/20 0.48
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
ATM Q13315 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
GAA P10253 1/20 0.46
LMNA P02545 2/20 0.46
CYP1A2 P05177 1/20 0.46
GLA P06280 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27915383 0.84 KMT2A (0.59) MEN1KMT2AHTTALDH1A1HPGD
SCHEMBL6943603 0.84 MEN1 (0.58) MEN1KMT2AHTTALDH1A1HPGD
SCHEMBL5190460 0.84 KMT2A (0.58) MEN1KMT2AHTTALDH1A1HPGD
SCHEMBL6629591 0.84 MEN1 (0.58) MEN1KMT2AHTTALDH1A1HPGD
SCHEMBL5758426 0.82 KMT2A (0.57) MEN1KMT2AHTTALDH1A1HPGD
SCHEMBL9042374 0.81 MEN1 (0.57) MEN1KMT2AHTTALDH1A1HPGD
SCHEMBL15140305 0.80 MEN1 (0.54) MEN1KMT2AHTTALDH1A1HPGD
SCHEMBL27630670 0.80 ALDH1A1 (0.62) MEN1KMT2AHTTALDH1A1HPGD
SCHEMBL13134244 0.80 MEN1 (0.54) MEN1KMT2AHTTALDH1A1HPGD
SCHEMBL5190453 0.79 MEN1 (1.00) MEN1KMT2AHTTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931316-B1 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ACID LABILE DRUGS SOLVAY PHARM GMBH (DE) 2010-02-17 EP claimed
EP-0992511-B1 Methods and compositions for determining the sequence of nucleic acid molecules OPERON BIOTECHNOLOGIES INC (US) 2009-03-11 EP claimed
EP-0868535-B9 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES QIAGEN GENOMICS INC (US) 2007-05-09 EP claimed
EP-0868535-B2 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES QIAGEN GENOMICS INC (US) 2006-01-04 EP claimed
EP-0934276-B1 ANTHRANILIC ACID DERIVATIVES AS MULTI DRUG RESISTANCE MODULATORS XENOVA LTD (GB) 2003-12-17 EP claimed
EP-1028164-B1 Microbial conversion of 2-methylquinoxaline PFIZER PROD INC (US) 2003-11-12 EP claimed
EP-0691970-A1 IMIDAZOLOQUINOXALINONE DERIVATIVES AS EAA ANTAGONISTS BASF AKTIENGESELLSCHAFT (DE) 1996-01-17 EP claimed
WO-1994022865-A1 IMIDAZOLOQUINOXALINONE DERIVATIVES AS EAA ANTAGONISTS BASF AKTIENGESELLSCHAFT (DE) 1994-10-13 WO claimed
EP-0944582-B1 KETOBENZAMIDES AS CALPAIN INHIBITORS ABBOTT GMBH & CO KG (DE) 2003-07-02 EP disclosed
EP-0944582-A1 KETOBENZAMIDES AS CALPAIN INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 1999-09-29 EP disclosed
WO-1998025883-A1 KETOBENZAMIDES AS CALPAIN INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 1998-06-18 WO disclosed
EP-0691970-A1 IMIDAZOLOQUINOXALINONE DERIVATIVES AS EAA ANTAGONISTS BASF AKTIENGESELLSCHAFT (DE) 1996-01-17 EP disclosed
EP-0513543-B1 Derivatives of amidinophenylalanine, procedure for their preparation, their utilisation and anticoagulant compositions comprising them. BEHRINGWERKE AG (DE) 1995-10-25 EP disclosed
WO-1994022865-A1 IMIDAZOLOQUINOXALINONE DERIVATIVES AS EAA ANTAGONISTS BASF AKTIENGESELLSCHAFT (DE) 1994-10-13 WO disclosed
EP-0513543-A1 Derivatives of amidinophenylalanine, procedure for their preparation, their utilisation and anticoagulant compositions comprising them. BEHRINGWERKE Aktiengesellschaft (DE) 1992-11-19 EP disclosed
EP-0292729-B1 PROCESS FOR SOLID PHASE PEPTIDE SYNTHESIS BACHEM AG (CH) 1992-04-22 EP disclosed
EP-0292729-A2 Process for solid phase peptide synthesis BACHEM AG (CH) 1988-11-30 EP disclosed